LX102
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for LX102, covering 2025-07-01 to 2026-03-06. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS) [Phase 2]